* Eledon Pharmaceuticals Inc reported a quarterly adjusted loss of 29 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -69 cents. The mean expectation of six analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -45 cents to -35 cents per share.
* Reported revenue was zero; analysts expected zero.
* Eledon Pharmaceuticals Inc's reported EPS for the quarter was a loss of 29 cents.
* The company reported a quarterly loss of $9.63 million.
* Eledon Pharmaceuticals Inc shares had risen by 18.3% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $10.00 This summary was machine generated from LSEG data March 28 at 09:02 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.39 -0.29 Beat
Sep. 30 2023 -0.46 -0.35 Beat
Jun. 30 2023 -0.46 -0.40 Beat
Mar. 31 2023 -0.60 -0.75 Missed
Comments